Ethics Subcommittee, Advisory Committee to the Director, Centers for Disease Control and Prevention (CDC); Meeting, 52663 [E8-20967]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 176 / Wednesday, September 10, 2008 / Notices
there was a red tide and then examined
the data to see if red tide exposure had
an effect on symptom reports or PFT
results.
NCEH requests a revision of data
collection procedures for the currently
approved project and an additional
three year extension. Unfortunately, the
exposures experienced by the study
cohort have been minimal, and NCEH
plans to conduct another study (using
the same symptom surveys and PFTs)
during a more severe red tide event.
First, NCEH wants to quantify the levels
of cytokines in nasal exudates to assess
whether they can be used to verify
exposure and to demonstrate a
biological effect (i.e., allergic response)
following inhalation of aerosolized
brevetoxins. NCEH will collect nasal
52663
exudates at the same time the PFTs are
done.
NCEH plans to include the study
subjects who have been involved in the
earlier studies and any new individuals
(n=25) who have been hired to work at
the relevant beaches.
There is no cost to respondents other
than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Number of respondents
Number of responses per
respondent
Pulmonary History Survey ...............................................................................
Symptom survey ..............................................................................................
10
25
1
6
20/60
5/60
3
13
Total ..........................................................................................................
........................
........................
........................
16
Instrument type
Catina Conner,
Assistant Reports Clearance Officer, Centers
for Disease Control and Prevention.
[FR Doc. E8–20913 Filed 9–9–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Ethics Subcommittee, Advisory
Committee to the Director, Centers for
Disease Control and Prevention (CDC);
Meeting
pwalker on PROD1PC71 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention announce the
following Subcommittee meeting.
Name: Ethics Subcommittee, Advisory
Committee to the Director.
Time and Date: 12 p.m.–1:30 p.m., EDT,
Thursday, September 25, 2008.
Place: This meeting will be held by
conference call. The call in number is (866)
919–3560 and entering code 4168828.
Status: Open to the public. The public is
welcome to comment during the public
comment period which is tentatively
scheduled from 1 p.m.–1:15 p.m.
Purpose: The Ethics Subcommittee will
provide counsel to the ACD, CDC regarding
a broad range of public health ethics
questions and issues arising from programs,
scientists and practitioners.
Matters To Be Discussed: Agenda items
will include review of ethics guidance for
public health emergency preparedness and
response.
For Further Information Contact: For more
information about this meeting contact Drue
Barrett, PhD., Designated Federal Official,
Ethics Subcommittee, CDC, 1600 Clifton
Road, NE., M/S D–50, Atlanta, Georgia
VerDate Aug<31>2005
16:52 Sep 09, 2008
Jkt 214001
30333, Telephone (404)639–4690, e-mail:
dbarrett@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: September 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–20967 Filed 9–9–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0239]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Regulations for In
Vivo Radiopharmaceuticals Used for
Diagnosis and Monitoring
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by October 10,
2008.
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Total burden
(in hours)
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0409. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Information Management (HFA–710),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–796–3792.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Regulations for In Vivo
Radiopharmaceuticals Used for
Diagnosis and Monitoring (OMB
Control Number 0910–0409)—Extension
FDA is requesting OMB approval of
the information collection requirements
contained in 21 CFR 315.4, 315.5, and
315.6. These regulations require
manufacturers of diagnostic
radiopharmaceuticals to submit
information that demonstrates the safety
and effectiveness of a new diagnostic
radiopharmaceutical or of a new
indication for use of an approved
diagnostic radiopharmaceutical.
In response to the requirements of
section 122 of the Food and Drug
Administration Modernization Act of
1997 (Public Law 105–115), FDA
published a final rule in the Federal
E:\FR\FM\10SEN1.SGM
10SEN1
]]>Agencies
[Federal Register Volume 73, Number 176 (Wednesday, September 10, 2008)]
[Notices]
[Page 52663]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-20967]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Ethics Subcommittee, Advisory Committee to the Director, Centers
for Disease Control and Prevention (CDC); Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention announce the following Subcommittee meeting.
Name: Ethics Subcommittee, Advisory Committee to the Director.
Time and Date: 12 p.m.-1:30 p.m., EDT, Thursday, September 25,
2008.
Place: This meeting will be held by conference call. The call in
number is (866) 919-3560 and entering code 4168828.
Status: Open to the public. The public is welcome to comment
during the public comment period which is tentatively scheduled from
1 p.m.-1:15 p.m.
Purpose: The Ethics Subcommittee will provide counsel to the
ACD, CDC regarding a broad range of public health ethics questions
and issues arising from programs, scientists and practitioners.
Matters To Be Discussed: Agenda items will include review of
ethics guidance for public health emergency preparedness and
response.
For Further Information Contact: For more information about this
meeting contact Drue Barrett, PhD., Designated Federal Official,
Ethics Subcommittee, CDC, 1600 Clifton Road, NE., M/S D-50, Atlanta,
Georgia 30333, Telephone (404)639-4690, e-mail: dbarrett@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Dated: September 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E8-20967 Filed 9-9-08; 8:45 am]
BILLING CODE 4163-18-P
